Is ArriVent BioPharma, Inc. (AVBP) a Buy, Sell, or Hold?
ArriVent BioPharma, Inc.
NASDAQ:AVBP
$32.54 USD
-$1.1 (-3.27%)
- Volume
- 293.31K
- Average Volume
- 548.21K
- Market Capitalization
- $1.52B
- P/E Ratio
- -9.22
- Dividend Yield
- 0.00%
- Price Target
- $45.00
- Year High
- $35.83
- Year Low
- $16.10
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $13.95
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
13
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
4
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$ 566.71K
AVBP Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
AVBP Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Parsey Merdad | director | 2026-06-18 | A-Award | 31.74 | 2026-06-22 |
| Peterson Kristine | director | 2026-06-18 | A-Award | 31.74 | 2026-06-22 |
| Hohneker John | director | 2026-06-18 | A-Award | 31.74 | 2026-06-22 |
| Nolet Chris | director | 2026-06-18 | A-Award | 31.74 | 2026-06-22 |
| LaChapelle Robin | officer: Chief Operating Officer | 2026-02-02 | A-Award | 22.67 | 2026-02-04 |
| Lutzker Stuart | director, officer: President of R&D | 2026-02-02 | A-Award | 22.67 | 2026-02-04 |
| Kung Winston | officer: Chief Financial Officer | 2026-02-02 | A-Award | 22.67 | 2026-02-04 |
| Yao Zhengbin | director, officer: President and CEO | 2026-02-02 | A-Award | 22.67 | 2026-02-04 |
| Kastenmayer James Paul | officer: General Counsel | 2026-02-02 | A-Award | 22.67 | 2026-02-04 |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 2025-12-10 | S-Sale | 23.37 | 2026-02-03 |
| LaChapelle Robin | officer: Chief Operating Officer | 2025-07-11 | M-Exempt | 2.28 | 2025-07-15 |
| LaChapelle Robin | officer: Chief Operating Officer | 2025-07-11 | M-Exempt | 2.28 | 2025-07-15 |
| LaChapelle Robin | officer: Chief Operating Officer | 2025-07-11 | M-Exempt | 2.28 | 2025-07-15 |
| LaChapelle Robin | officer: Chief Operating Officer | 2025-07-11 | M-Exempt | 2.28 | 2025-07-15 |
| LaChapelle Robin | officer: Chief Operating Officer | 2025-07-11 | M-Exempt | 2.28 | 2025-07-15 |
| LaChapelle Robin | officer: Chief Operating Officer | 2025-07-11 | M-Exempt | 2.28 | 2025-07-15 |
| Parsey Merdad | director | 2025-06-18 | A-Award | 24.89 | 2025-06-20 |
| Peterson Kristine | director | 2025-06-18 | A-Award | 24.89 | 2025-06-20 |
| Hohneker John | director | 2025-06-18 | A-Award | 24.89 | 2025-06-20 |
| Nolet Chris | director | 2025-06-18 | A-Award | 24.89 | 2025-06-20 |
| Parsey Merdad | director | 2025-04-28 | A-Award | 20.92 | 2025-04-29 |
| Parsey Merdad | director: | 2025-04-28 | 0 | 2025-04-29 | |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 2024-01-30 | P-Purchase | 18 | 2024-02-01 |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 2024-01-30 | C-Conversion | 0 | 2024-02-01 |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 2024-01-30 | C-Conversion | 0 | 2024-02-01 |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 2024-01-30 | C-Conversion | 0 | 2024-02-01 |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 2024-01-30 | C-Conversion | 0 | 2024-02-01 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | 2024-01-30 | P-Purchase | 18 | 2024-01-31 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | 2024-01-30 | C-Conversion | 0 | 2024-01-31 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | 2024-01-30 | C-Conversion | 0 | 2024-01-31 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | 2024-01-30 | C-Conversion | 0 | 2024-01-31 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | 2024-01-30 | C-Conversion | 0 | 2024-01-31 |
| GORDON CARL L | director, 10 percent owner: | 2024-01-30 | P-Purchase | 18 | 2024-01-31 |
| GORDON CARL L | director, 10 percent owner: | 2024-01-30 | C-Conversion | 0 | 2024-01-31 |
| GORDON CARL L | director, 10 percent owner: | 2024-01-30 | C-Conversion | 0 | 2024-01-31 |
| GORDON CARL L | director, 10 percent owner: | 2024-01-30 | C-Conversion | 0 | 2024-01-31 |
| GORDON CARL L | director, 10 percent owner: | 2024-01-30 | C-Conversion | 0 | 2024-01-31 |
| HEALY JAMES | director | 2024-01-30 | P-Purchase | 18 | 2024-01-31 |
| HEALY JAMES | director | 2024-01-30 | C-Conversion | 0 | 2024-01-31 |
| HEALY JAMES | director | 2024-01-30 | C-Conversion | 0 | 2024-01-31 |
| Nolet Chris | director | 2024-01-25 | A-Award | 18 | 2024-01-29 |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 2024-01-25 | 0 | 2024-01-25 | |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 2024-01-25 | 0 | 2024-01-25 | |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | 2024-01-25 | 0 | 2024-01-25 | |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | 2024-01-25 | 0 | 2024-01-25 | |
| Nolet Chris | director | 2024-01-25 | 6.24 | 2024-01-25 | |
| Kung Winston | officer: Chief Financial Officer | 2024-01-25 | 7.76 | 2024-01-25 | |
| Kastenmayer James Paul | officer: General Counsel | 2024-01-25 | 0 | 2024-01-25 | |
| Kastenmayer James Paul | officer: General Counsel | 2024-01-25 | 6.24 | 2024-01-25 | |
| Kastenmayer James Paul | officer: General Counsel | 2024-01-25 | 7.76 | 2024-01-25 | |
| HEALY JAMES | director | 2024-01-25 | 0 | 2024-01-25 | |
| GORDON CARL L | director, 10 percent owner: | 2024-01-25 | 0 | 2024-01-25 | |
| GORDON CARL L | director, 10 percent owner: | 2024-01-25 | 0 | 2024-01-25 |